A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2011
This article has no abstract
Epistemonikos ID: fba203ba4fa1cce726131382f93fff3e581dd115
First added on: Feb 04, 2025